Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does IXEKIZUMAB Cause Contraindicated product administered? 34 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 34 reports of Contraindicated product administered have been filed in association with IXEKIZUMAB (TALTZ). This represents 0.1% of all adverse event reports for IXEKIZUMAB.

34
Reports of Contraindicated product administered with IXEKIZUMAB
0.1%
of all IXEKIZUMAB reports
0
Deaths
21
Hospitalizations

How Dangerous Is Contraindicated product administered From IXEKIZUMAB?

Of the 34 reports, 21 (61.8%) required hospitalization, and 1 (2.9%) were considered life-threatening.

Is Contraindicated product administered Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for IXEKIZUMAB. However, 34 reports have been filed with the FAERS database.

What Other Side Effects Does IXEKIZUMAB Cause?

Injection site pain (3,799) Psoriasis (2,818) Drug ineffective (2,759) Injection site erythema (2,144) Injection site reaction (1,701) Injection site swelling (1,615) Incorrect dose administered (1,032) Covid-19 (861) Product dose omission issue (832) Therapy interrupted (796)

What Other Drugs Cause Contraindicated product administered?

ABATACEPT (13,559) METHOTREXATE (13,121) ETANERCEPT (12,062) TOCILIZUMAB (11,547) ADALIMUMAB (11,270) LEFLUNOMIDE (11,206) HYDROXYCHLOROQUINE (10,557) RITUXIMAB (10,479) INFLIXIMAB (9,618) SULFASALAZINE (8,698)

Which IXEKIZUMAB Alternatives Have Lower Contraindicated product administered Risk?

IXEKIZUMAB vs JAKAFI IXEKIZUMAB vs JANUMET IXEKIZUMAB vs JANUVIA IXEKIZUMAB vs JETREA IXEKIZUMAB vs JUXTAPID

Related Pages

IXEKIZUMAB Full Profile All Contraindicated product administered Reports All Drugs Causing Contraindicated product administered IXEKIZUMAB Demographics